MR-US Image Fusion Targeted Biopsy for Single-cell Prostate Cancer Research
| Status: | Recruiting |
|---|---|
| Conditions: | Prostate Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 1/11/2018 |
| Start Date: | July 2013 |
| End Date: | October 2018 |
| Contact: | Preston Sprenkle, MD |
| Email: | Preston.Sprenkle@yale.edu |
The investigators hypothesize that this single-cell analysis can be used to evaluate prostate
needle-core biopsies prospectively even in non-homogenous samples by providing profiles of
proteomic and phenotypic signatures. These profiles will in turn enable better predictions of
the malignant progression of prostate cancers in the settings of current clinical practice.
needle-core biopsies prospectively even in non-homogenous samples by providing profiles of
proteomic and phenotypic signatures. These profiles will in turn enable better predictions of
the malignant progression of prostate cancers in the settings of current clinical practice.
Current approaches for early detection and diagnosis include prostate-specific antigen (PSA)
which is a useful, though not specific, biomarker for detecting prostate cancer. The
suspected patients will be further sent for digital rectal examination(DRE), in which a
doctor inserts a lubricated, gloved finger into the patient's rectum to feel for lumps,
enlargements, or areas of hardness that might indicate prostate cancer. However, the only
test that can fully confirm the diagnosis of prostate cancer is a biopsy - the removal of
small pieces of the prostate for microscopic examination. If cancer is suspected using PSA
test and DRE, more than 90% suspected patients choose undergo prostate biopsy. Prostate
needle biopsies are routinely done on an outpatient basis and rarely require hospitalization.
Markedly, the fine needle biopsy is minimally invasive and has currently been suggested for
longitudinal monitoring of highly suspected patients or follow-up therapeutic responses. The
large availability of biopsy samples for prostate cancer provides a cornerstone for the
proposed patient specimen-based research. The investigators anticipate that comprehensive
analysis rather than simple pathological examination of these samples will generate new
insights to prostate tumor progression in human.
which is a useful, though not specific, biomarker for detecting prostate cancer. The
suspected patients will be further sent for digital rectal examination(DRE), in which a
doctor inserts a lubricated, gloved finger into the patient's rectum to feel for lumps,
enlargements, or areas of hardness that might indicate prostate cancer. However, the only
test that can fully confirm the diagnosis of prostate cancer is a biopsy - the removal of
small pieces of the prostate for microscopic examination. If cancer is suspected using PSA
test and DRE, more than 90% suspected patients choose undergo prostate biopsy. Prostate
needle biopsies are routinely done on an outpatient basis and rarely require hospitalization.
Markedly, the fine needle biopsy is minimally invasive and has currently been suggested for
longitudinal monitoring of highly suspected patients or follow-up therapeutic responses. The
large availability of biopsy samples for prostate cancer provides a cornerstone for the
proposed patient specimen-based research. The investigators anticipate that comprehensive
analysis rather than simple pathological examination of these samples will generate new
insights to prostate tumor progression in human.
Inclusion Criteria:
- Only subjects that have scheduled Artemis prostate biopsy with defined regions of
interest will be included in this study
Exclusion Criteria:
- Any subjects that are unable to provide informed consent will be excluded
We found this trial at
1
site
New Haven, Connecticut 6520
(203) 432-4771
Principal Investigator: Preston Sprenkle, MD
Yale University Yale's roots can be traced back to the 1640s, when colonial clergymen led...
Click here to add this to my saved trials
